In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on Accolade (ACCD – Research Report), with a price target of $14.00. The company’s shares closed yesterday at $9.19.
According to TipRanks, Singh is an analyst with an average return of -13.9% and a 31.82% success rate. Singh covers the Healthcare sector, focusing on stocks such as R1 RCM, Icon, and IQVIA Holdings.
In addition to Truist Financial, Accolade also received a Buy from Needham’s Ryan MacDonald in a report issued today. However, on the same day, Morgan Stanley maintained a Hold rating on Accolade (NASDAQ: ACCD).
Based on Accolade’s latest earnings release for the quarter ending November 30, the company reported a quarterly revenue of $99.37 million and a GAAP net loss of $21.06 million. In comparison, last year the company earned a revenue of $90.95 million and had a GAAP net loss of $39.87 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Accolade (ACCD) Company Description:
Accolade Inc offers technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. it generates revenue through providing personalized health guidance solutions to members.
